4D Molecular Therapeutics, Inc. (FDMT) SEC Filings & Earnings Calls

Clinical trial risk: Phase 3 4SIGHT trial is ongoing; results may differ from SPECTRA; supplemental injection criteria differences could affect outcomes

“retrospective estimate, actual results in 4SIGHT may differ” · word for word

Clinical trial risk: 4D-150 Phase 3 data expected in 2027; failure could impact pipeline value.

“Topline data for 4FRONT-1 expected Q2 2027; 4FRONT-2 expected H2 2027.”

Operating losses and high cash burn rate; net loss $72.9M in Q2.

“Net loss was $72.9 million for Q2 2026, compared to $54.7 million in Q2 2025.” · word for word

Significant operating losses and negative cash flows

“The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $858.0 million as of June 30, 2026.” · word for word

Dependence on additional financing

“Management expects operating losses and negative cash flows from operations to continue for the foreseeable future.” · word for word

Clinical trial risk

“Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization, which could seriously harm our business.” · word for word

Clinical trial risk remains; Phase 3 outcomes not yet known; regulatory approval uncertain.

“Forward-looking statements caution about risks; Phase 3 trials ongoing.”

IP collateral risk: loan secured by substantially all assets including intellectual property, increasing risk of loss in default.

“The Company’s obligations under the Agreement are secured by substantially all of its assets, including its intellectual property.” · word for word

Financial covenant risk: minimum cash and performance covenants could trigger default if milestones not met or cash runs low.

“The Agreement contains the following financial covenants: (i) a minimum cash covenant... (ii) a performance covenant that is tested beginning nine months after FDA approval” · word for word

Pre-revenue clinical-stage biotech with significant cash burn

“The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $785.1 million as of March 31, 2026.” · word for word

Dependence on Otsuka collaboration for near-term revenue

“Customer A (Otsuka) represented 97% of total revenue for the three months ended March 31, 2026.”

Clinical trial and regulatory uncertainty

“All of our product candidates are based on a novel AAV genetic medicine technology with which there is limited regulatory and clinical experience to date.” · word for word

Clinical trial failure risk; 4D-150 Phase 3 data not expected until H1 2027.

“Topline data expected in H1 2027; long wait for pivotal readout.”

Cash burn rate increasing; net loss widened 43% YoY.

“Net loss was $68.8 million for Q1 2026 vs $48.0 million for Q1 2025.” · word for word

Pre-funded warrants create potential dilution

“16,935,665 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of the Record Date (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations).” · word for word

Net loss trajectory worsening

“Net Income (thousands) ($) 2025 (140,109) ... 2024 (160,868) ... 2023 (100,837)”

No approved products; no product revenue

“We have no products approved for commercial sale and have not generated any product revenue.” · word for word

Substantial additional capital required

“We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.” · word for word

Clinical trial risk: 4D-150 Phase 3 data not expected until H1 2027; potential for failure.

“Topline data expected in H1 2027; clinical trial outcomes are uncertain.”

Cash burn: No revenue; operating losses continue; reliance on cash reserves.

“Net loss per share $(0.49); cash runway into H2 2028 but no revenue.”

Regulatory risk: FDA/EMA approval not guaranteed.

“Phase 3 trials ongoing; regulatory approval required for commercialization.”

Potential dilution from pre-funded warrants exercisable at $0.0001 per share; 16.9M shares issuable

“16,935,665 shares of common stock issuable upon exercise of pre-funded warrants outstanding as of Jan 23, 2026, immediately exercisable at $0.0001 per share” · word for word

Key executive departure may create transition risk

“President and COO resigned effective immediately, though transition to part-time advisor role”

Clinical trial execution risk; enrollment and regulatory approval uncertainties.

“The Amendments support the Company’s planned global regulatory submissions for 4D-150” · word for word

Cash runway risk

“Cash, cash equivalents and marketable securities as of September 30, 2025 are sufficient for at least one year, but the company has an accumulated deficit of $735.7 million and expects continued losses.” · word for word

Dependence on future financing

“Management expects operating losses and negative cash flows to continue and plans to raise additional funding.” · word for word

Dilution from equity offering; lock-up period until Jan 6, 2026.

“8.39M shares and 1.13M pre-funded warrants issued; lock-up agreement.”

Clinical trial data is interim and may not predict final results.

“Data cutoff August 22, 2025; some cohorts have pending data for later timepoints.”

Clinical trial risk: Otsuka can terminate if Phase 3 trials fail primary endpoints.

“Otsuka may terminate the Agreement due to safety reasons or the failure of certain of the Company’s related clinical trials to achieve their primary endpoints.”